Results 21 to 30 of about 32,467 (248)
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? [PDF]
European Respiratory Journal, 2009 Possible masking of tuberculosis (TB) in treatment of community-acquired respiratory infection by newer fluoroquinolones has not been examined in randomised controlled trials.We undertook a randomised, open-label controlled trial involving adults with community-acquired pneumonia or infective exacerbation of bronchiectasis encountered in government ...
Kwok Chiu Chang +11 more
openalex +4 more sources
Bengal Journal of Otolaryngology and Head Neck Surgery, 2013 Antibiotic resistance among respiratory tract pathogens is increasing worldwide. Beta-lactam-resistant as well as macrolide and fluoroquinolone-resistant strains of the commonest pathogens are being isolated with increasing frequency in manycountries .
Soma Sarkar +3 more
doaj +1 more source
Bordetella bronchiseptica pneumonia in an immunocompetent pig farmer
IDCases, 2022 Bordetella bronchiseptica is a gram negative bacterium, a common pathogen in respiratory infections of various mammals, mainly dogs and pigs, being extremely rare in humans, occurring in these cases especially in immunosuppressed individuals.
José María Barcala Salido +2 more
doaj +1 more source
CLINICAL PHARMACOLOGY OF FLOROCHINOLONS: A FOCUS ON SAFETY. Review
Медична наука України, 2019 Fluoroquinolones are effective in the treatment of infections of almost any localization (upper and lower respiratory tract, urinary system, skin and soft tissues, bones and joints, liver and bile ducts, gastrointestinal tract, female genital tract ...
M.V. Khaitovych
doaj +1 more source
Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
Медицинский совет, 2014 The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired ...
A. I. Sinopalnikov
doaj +1 more source
Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]
, 2015 Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W +6 more
core +2 more sources
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV
Viruses, 2020 Repurposing FDA-approved drugs that treat respiratory infections caused by coronaviruses, such as SARS-CoV-2 and MERS-CoV, could quickly provide much needed antiviral therapies.
Stacey L. P. Scroggs +7 more
doaj +1 more source
Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones [PDF]
Clinical Infectious DiseasesAbstract Background Fluoroquinolones lack approval for treatment of tularemia but have been used extensively for milder illness. Here, we evaluated fluoroquinolones for severe illness. Methods In an observational study, we identified ...
Micael Widerström +4 more
openalex +4 more sources
Медицинский совет, 2013 The latest, so-called respiratory, fluoroquinolones are a group of antimicrobial agents (AMA), most commonly prescribed for community-acquired lower respiratory tract infection (caLRTI), which is a relevant issue in routine clinical practice.
A. I. Sinopalnikov
doaj +1 more source
Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014–2017» [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2019 Objective. To evaluate antimicrobial resistance patterns of clinical Streptococcus pneumoniae isolates from different regions of Russia during 2014–2017. Materials and Methods. We included in the study 519 clinical S.
Ivanchik N.V. +32 more
doaj +1 more source